Furthermore, after analyzing the importance of ATRX mutation in patients with GBM, Gülten et al. concluded that the loss of ATRX expression in GBM was a biomarker for predicting better survival rates: median overall survival with loss of ATRX expression was 15 months, while median overall survival without loss of ATRX expression was 8 months [135]. The gene discussed is ATRX; the disease is glioblastoma.